Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 3, 2009, Pages 397-403

  O'Byrne, Paul M ^a   Gauvreau, Gail M ^a   Murphy, Desmond M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

antagonists; Asthma; leukotrienes; synthesis inhibitors; treatment; treatment guidelines

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASPIRIN INDUCED ASTHMA; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; EOSINOPHILIC VASCULITIS; EXERCISE INDUCED ASTHMA; EYE TOXICITY; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN TOXICITY; VASCULITIS;

ADRENAL CORTEX HORMONES; ALLERGENS; ANTI-ASTHMATIC AGENTS; ASTHMA; CYSTEINE; EOSINOPHILS; HUMANS; IMMUNOLOGIC FACTORS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES;

EID: 69349096059     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.05.029     Document Type: Review

References (82)

1. Kellaway C.H., and Trethewie E.R. Liberation of slow-reacting smooth muscle stimulating substance in anaphylaxis. QJM 30 (1940) 121-145
2. Hammarstrom S., Samuelsson B., Clark D.A., Goto G., Marfat A., Mioskowski C., et al. Stereochemistry of leukotriene C-1. Biochem Biophys Res Commun 92 (1980) 946-953
3. Samuelsson B., and Hammarstrom S. Nomenclature for leukotrienes. Prostaglandins 19 (1980) 645-648
4. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
5. Lam B.K., Xu K., Atkins M.B., and Austen K.F. Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4. Proc Natl Acad Sci U S A 89 (1992) 11598-11602
6. Radmark O., Malmsten C., Samuelsson B., Clark D.A., Goto G., Marfat A., et al. Leukotriene A: stereochemistry and enzymatic conversion to leukotriene B. Biochem Biophys Res Commun 92 (1980) 954-961
7. Dahlen S.E., Hedqvist P., Hammarstrom S., and Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 288 (1980) 484-486
8. Weiss J.W., Drazen J.M., Coles N., McFadden Jr. E.R., Weller P.F., Corey E.J., et al. Bronchoconstrictor effects of leukotriene C in humans. Science 216 (1982) 196-198
9. Dahlen S.E., Bjork J., Hedqvist P., Arfors K.E., Hammarstrom S., Lindgren J.A., et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A 78 (1981) 3887-3891
10. Laitinen L.A., Laitinen A., Haahtela T., Vilkka V., Spur B.W., and Lee T.H. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341 (1993) 989-990
11. Coles S.J., Neill K.H., Reid L.M., Austen K.F., Nii Y., Corey E.J., et al. Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 25 (1983) 155-170
12. Cohen P., Noveral J.P., Bhala A., Nunn S.E., Herrick D.J., and Grunstein M.M. Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol Lung Cell Mol Physiol 269 (1995) L151-L157
13. Parameswaran K., Watson R., Gauvreau G.M., Sehmi R., and O'Byrne PM. The effect of pranlukast on allergen-induced bone marrow eosinophilopoiesis in subjects with asthma. Am J Respir Crit Care Med 169 (2004) 915-920
14. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.S., et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275 (2000) 30531-30536
15. Lynch K.R., O'Neill G.P., Liu Q., Im D.S., Sawyer N., Metters K.M., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 (1999) 789-793
16. Maekawa A., Kanaoka Y., Xing W., and Austen K.F. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105 (2008) 16695-16700
17. Masuda K., Yokomizo T., Izumi T., and Shimizu T. cDNA cloning and characterization of guinea-pig leukotriene B4 receptor. Biochem J 342 (1999) 79-85
18. Yokomizo T., Kato K., Terawaki K., Izumi T., and Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192 (2000) 421-432
19. Manning P.J., Rokach J., Malo J.L., Ethier D., Cartier A., Girard Y., et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol 86 (1990) 211-220
20. Kikawa Y., Miyanomae T., Inoue Y., Saito M., Nakai A., Shigematsu Y., et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 89 (1992) 1111-1119
21. Anderson S.D., and Daviskas E. The mechanism of exercise-induced asthma is.... J Allergy Clin Immunol 106 (2000) 453-459
22. Manning P.J., Watson R.M., Margolskee D.J., Williams V.C., Schwartz J.I., and O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 323 (1990) 1736-1739
23. Finnerty J.P., Wood-Baker R., Thomson H., and Holgate S.T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 145 (1992) 746-749
24. Leff J.A., Busse W.W., Pearlman D., Bronsky E.A., Kemp J., Hendeles L., et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 339 (1998) 147-152
25. Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 323 (1990) 1740-1744
26. Meltzer S.S., Hasday J.D., Cohn J., and Bleecker E.R. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 153 (1996) 931-935
27. Adelroth E., Inman M.D., Summers E., Pace D., Modi M., and O'Byrne PM. Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol 99 (1997) 210-215
28. Edelman J.M., Turpin J.A., Bronsky E.A., Grossman J., Kemp J.P., Ghannam A.F., et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 132 (2000) 97-104
29. O'Byrne P.M., Dolovich J., and Hargreave F.E. Late asthmatic responses. Am Rev Respir Dis 136 (1987) 740-751
30. Gauvreau G.M., Watson R.M., and O'Byrne PM. Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med 160 (1999) 640-647
31. Cartier A., Thomson N.C., Frith P.A., Roberts R., and Hargreave F.E. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 70 (1982) 170-177
32. Taylor I.K., O'Shaughnessy KM., Fuller RW., and Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337 (1991) 690-694
33. Rasmussen J.B., Eriksson L.O., Margolskee D.J., Tagari P., Williams V.C., and Andersson K.E. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 90 (1992) 193-201
34. Diamant Z., Timmers M.C., van d V., Friedman B.S., De S.M., Depre M., et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 95 (1995) 42-51
35. Hamilton A.L., Watson R.M., Wyile G., and O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 52 (1997) 348-354
36. Davis B.E., Illamperuma C., Gauvreau G.M., Watson R.M., O'Byrne P.M., Deschesnes F., et al. Single dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J 33 (2009) 1302-1308
37. Hamilton A., Faiferman I., Stober P., Watson R.M., and O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 102 (1998) 177-183
38. Leigh R., Vethanayagam D., Yoshida M., Watson R.M., Rerecich T., Inman M.D., et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 166 (2002) 1212-1217
39. Gauvreau G.M., Parameswaran K.N., Watson R.M., and O'Byrne PM. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 164 (2001) 1495-1500
40. Austen K.F., Maekawa A., Kanaoka Y., and Boyce J.A. The leukotriene E4 puzzle; finding the missing pieces and revealing the pathobiological implications. J Allergy Clin Immunol 124 (2009) 406-414
41. Calhoun W.J., Lavins B.J., Minkwitz M.C., Evans R., Gleich G.J., and Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 157 (1998) 1381-1389
42. Kane G.C., Pollice M., Kim C.J., Cohn J., Dworski R.T., Murray J.J., et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 97 (1996) 646-654
43. Parameswaran K., Liang H., Fanat A., Watson R., Snider D.P., and O'Byrne PM. Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. J Allergy Clin Immunol 114 (2004) 73-79
44. Stevenson D.D., and Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118 (2006) 773-786
45. Cowburn A.S., Sladek K., Soja J., Adamek L., Nizankowska E., Szczeklik A., et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101 (1998) 834-846
46. Sampson A.P., Cowburn A.S., Sladek K., Adamek L., Nizankowska E., Szczeklik A., et al. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol 113 (1997) 355-357
47. Christie P.E., Smith C.M., and Lee T.H. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 144 (1991) 957-958
48. Dahlen B., Kumlin M., Margolskee D.J., Larsson C., Blomqvist H., Williams V.C., et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 6 (1993) 1018-1026
49. Nasser S.M., Bell G.S., Foster S., Spruce K.E., MacMillan R., Williams A.J., et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 49 (1994) 749-756
50. Israel E., Fischer A.R., Rosenberg M.A., Lilly C.M., Callery J.C., Shapiro J., et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148 (1993) 1447-1451
51. Dahlen B., Margolskee D.J., Zetterstrom O., and Dahlen S.E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 48 (1993) 1205-1210
52. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., Fitzgerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 (2008) 143-178
53. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120 suppl (2007) S94-S138
54. Barnes N.C., and Pujet J.C. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 52 (1997) 523-527
55. Gaddy J.N., Margolskee D.J., Bush R.K., Williams V.C., and Busse W.W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 146 (1992) 358-363
56. Spector S.L., Smith L.J., and Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 150 (1994) 618-623
57. Reiss T.F., Sorkness C.A., Stricker W., Botto A., Busse W.W., Kundu S., et al. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52 (1997) 45-48
58. Ferreira M.B., Santos A.S., Pregal A.L., Michelena T., Alonso E., de Sousa A.V., et al. Leukotriene receptor antagonists (montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris) 33 (2001) 315-318
59. Juniper E.F., O'Byrne PM., Guyatt GH., Ferrie PJ., and King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999) 902-907
60. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113 (2004) 59-65
61. Israel E., Cohn J., Dube L., and Drazen J.M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275 (1996) 931-936
62. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., and Edwards T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158 (1998) 1213-1220
63. Johnston N.W., Mandhane P.J., Dai J., Duncan J.M., Greene J.M., Lambert K., et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 120 (2007) e702-e712
64. Lange P., Parner J., Vestbo J., Schnohr P., and Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339 (1998) 1194-1200
65. Busse W., Raphael G.D., Galant S., Kalberg C., Goode-Sellers S., Srebro S., et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 107 (2001) 461-468
66. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
67. Bleecker E.R., Welch M.J., Weinstein S.F., Kalberg C., Johnson M., Edwards L., et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 105 (2000) 1123-1129
68. Juniper E.F., Kline P.A., Vanzieleghem M.A., Ramsdale E.H., O'Byrne PM., and Hargreave FE. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 3 (1990) 1122-1127
69. Kanniess F., Richter K., Bohme S., Jorres R.A., and Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 20 (2002) 853-858
70. Laitinen L.A., Laitinen A., and Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 90 (1992) 32-42
71. Hoshino M., Takahashi M., Takai Y., Sim J., and Aoike N. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 31 (2001) 722-730
72. Trigg C.J., Manolitsas N.D., Wang J., Calderon M.A., McAulay A., Jordan S.E., et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150 (1994) 17-22
73. Ram F.S., Cates C.J., and Ducharme F.M. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev (2005) (1):CD003137
74. Nelson H.S., Busse W.W., Kerwin E., Church N., Emmett A., Rickard K., et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106 (2000) 1088-1095
75. Wechsler M.E., Garpestad E., Flier S.R., Kocher O., Weiland D.A., Polito A.J., et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 279 (1998) 455-457
76. Wechsler M.E., Finn D., Gunawardena D., Westlake R., Barker A., Haranath S.P., et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117 (2000) 708-713
77. Watkins P.B., Dube L.M., Walton-Bowen K., Cameron C.M., and Kasten L.E. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 30 (2007) 805-815
78. Szczeklik A., and Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 104 (1999) 5-13
79. Dahlen S.E., Malmstrom K., Nizankowska E., Dahlen B., Kuna P., Kowalski M., et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 9-14
80. Sears M.R., Burrows B., Flannery E.M., Herbison G.P., and Holdaway M.D. Atopy in childhood. I. Gender and allergen related risks for development of hay fever and asthma. Clin Exp Allergy 23 (1993) 941-948
81. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009) 985-993
82. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009) 973-984